Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 2/20 | 0.44 |
| ▸ | METAP1 | P53582 | 2/20 | 0.44 |
| ▸ | PRKCI | P41743 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5119781 | 0.90 | PRKCI (0.48) | PRKCILMNAHTTSMN1; SMN2 | |
| SCHEMBL5126030 | 0.90 | PRKCI (0.38) | PRKCILMNASMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL7611849 | 0.84 | MAPT (0.38) | PRKCILMNAHTTSMN1; SMN2 | |
| SCHEMBL5119049 | 0.84 | PDE5A (0.39) | LMNAHTTSMN1; SMN2ADORA2AADORA1 | |
| SCHEMBL5122356 | 0.82 | PRKCI (0.60) | METAP2METAP1PRKCIHTT | |
| SCHEMBL5129364 | 0.82 | HTT (0.43) | METAP2METAP1PRKCIHTTSMN1; SMN2 | |
| SCHEMBL5126310 | 0.82 | CHRM4 (0.41) | PRKCILMNAHTTSMN1; SMN2 | |
| SCHEMBL5115274 | 0.82 | METAP1 (0.68) | METAP2METAP1PRKCIADORA2AADORA1 | |
| SCHEMBL5816198 | 0.81 | FAAH (0.38) | LMNAHTTSMN1; SMN2ADORA2AADORA1 | |
| SCHEMBL5122881 | 0.80 | GBA1 (0.58) | METAP2METAP1PRKCILMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-6432950-B1 | ANTICANCER AGENTS; KILLING CANCER CELLS | CELL PATHWAYS | 2002-08-13 | — | — | US | disclosed |
| US-6110920-A | TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | TIE1, DPYD, TK2 | METAP2 860/4885METAP1 954/4885PRKCI 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.